| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | SEF; HH18; IL-17RD; IL17RLM |
| WB Predicted band size | 82 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human IL17RD |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
由于我无法直接访问实时数据库或具体文献内容，以下示例格式可供参考。建议通过PubMed、Google Scholar等平台搜索关键词“IL17RD antibody”获取真实文献：
---
**示例1**
**文献名称**: *IL17RD negatively regulates IL-17-mediated signaling via SEFIR domain interactions*
**作者**: Wang, Y. et al.
**摘要**: 研究揭示了IL17RD作为IL-17信号通路的负调控因子，通过其SEFIR结构域竞争性抑制IL-17RA的活化。实验采用IL17RD特异性抗体阻断功能，证实其在减轻小鼠结肠炎模型中的作用。
---
**示例2**
**文献名称**: *Antibody targeting of IL17RD enhances BMP signaling in osteosarcoma*
**作者**: Lee, H. et al.
**摘要**: 开发了一种抗IL17RD的单克隆抗体，发现其可通过抑制IL17RD与BMP受体的相互作用，增强骨肉瘤细胞的成骨分化，为治疗骨相关疾病提供潜在策略。
---
**示例3**
**文献名称**: *IL17RD expression correlates with prognosis in breast cancer and modulates ERK activation*
**作者**: Martinez, E. et al.
**摘要**: 通过免疫组化(使用抗IL17RD抗体)分析乳腺癌组织，发现IL17RD低表达与患者不良预后相关。体外实验表明IL17RD通过调控ERK磷酸化抑制肿瘤迁移。
---
**实际检索建议**：
1. 访问 **PubMed**(https://pubmed.ncbi.nlm.nih.gov)，搜索“IL17RD antibody”或“IL17RD function”。
2. 筛选近年文献，关注涉及抗体开发、信号机制或疾病模型的研究。
3. 查看综述文章(如*Cytokine & Growth Factor Reviews*)以追踪关键参考文献。
希望这些示例对您整理文献有所帮助!
IL17RD (Interleukin-17 Receptor D), also known as Sef (similar expression to fibroblast growth factor genes), is a transmembrane protein that belongs to the IL-17 receptor (IL-17R) family. Initially identified for its homology to fibroblast growth factor receptors (FGFRs), IL17RD functions as a dual regulator in both IL-17 and FGF signaling pathways. It acts as a feedback inhibitor, modulating downstream signaling by interacting with IL-17RA or FGFR1 to suppress NF-κB, MAPK, or other pathways, thereby influencing inflammatory responses, cell differentiation, and tissue homeostasis. Dysregulation of IL17RD has been implicated in autoimmune diseases, cancer, and developmental disorders.
Antibodies targeting IL17RD are essential tools for studying its expression, localization, and molecular interactions. These antibodies are commonly used in techniques such as Western blotting, immunohistochemistry, and flow cytometry to detect IL17RD in cell lines, tissues, or disease models. Some antibodies are designed to recognize specific epitopes, enabling the investigation of post-translational modifications or functional domains. Research utilizing IL17RD antibodies has revealed its tissue-specific expression patterns, reduced levels in certain cancers (e.g., prostate, breast), and regulatory roles in autoimmune conditions like psoriasis or rheumatoid arthritis. Additionally, therapeutic antibodies targeting IL17RD are being explored to modulate inflammatory pathways or disrupt oncogenic signaling networks, highlighting its potential as a biomarker or drug target.
×
